Brian Stuglik has been appointed CEO of Verastem Oncology (NASDAQ: [[ticker:VSTM]]). Stuglik is a member of the Boston-based cancer drug developer’s board of directors, and he will retain his board seat. His experience also includes various positions at Eli Lilly (NYSE: [[ticker:LLY]]). Stuglik succeeds Robert Forrester, who stepped down in June.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
